- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
| home:translations:polish [05.07.2018] – [Uruchamianie pacjenta Protokołu Marshalla] sallieq | home:translations:polish [05.10.2019] – [Data] sallieq | ||
|---|---|---|---|
| Line 24: | Line 24: | ||
| ===== Tło i naukowe uzasadnienia dla terapii ===== | ===== Tło i naukowe uzasadnienia dla terapii ===== | ||
| - | | + | |
| - | + | < | |
| - | + | * [[home:physicians: | |
| + | * [[home: | ||
| + | * [[home: | ||
| + | * [[home: | ||
| + | </ | ||
| Marshall Protocol (MP) to nazwa terapii opracowanej przez prof. Trevor' | Marshall Protocol (MP) to nazwa terapii opracowanej przez prof. Trevor' | ||
| Line 300: | Line 304: | ||
| Pacjenci, którzy zatrzymują olmesartan kończą się ich zwrotu. | Pacjenci, którzy zatrzymują olmesartan kończą się ich zwrotu. | ||
| + | ===== Data ===== | ||
| + | [[home: | ||
| + | |||
| + | [[home: | ||
| + | |||
| + | ==== Response in 5 diagnoses ==== | ||
| + | |||
| + | | ||
| + | |||
| + | SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91% | ||
| + | |||
| + | Sarcoidosis success 75.8% | ||
| + | |||
| + | Chronic Fatigue Syndrome success 60.1% | ||
| + | |||
| + | Lyme disease success 66.9% | ||
| + | |||
| + | Rheumatoid arthritis success 69.2% | ||
| + | |||
| + | Fibromyalgia success 64.2% | ||
| + | |||
| + | All Other Th1 disease success 59.8% | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| Line 324: | Line 350: | ||
| //added// “Pacjenci nie powinni przyjmować Nimesulid (Aulin / Mesulid / Nimed). To może powodować krwawienie. Jedna śmierć została zgłoszona w trakcie jej użytkowania.” //–Sallie Q …soon after that death occurred// | //added// “Pacjenci nie powinni przyjmować Nimesulid (Aulin / Mesulid / Nimed). To może powodować krwawienie. Jedna śmierć została zgłoszona w trakcie jej użytkowania.” //–Sallie Q …soon after that death occurred// | ||
| + | |||
| + | NOT - [[http:// | ||
| ===== Referencje | ===== Referencje | ||
home/translations/polish.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.